People: Uroplasty Inc (UPI.PH)

UPI.PH on Philadelphia Stock Exchange

2.25USD
5 Nov 2014
Price Change (% chg)

-- (--)
Prev Close
$2.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5
52-wk High
$4.66
52-wk Low
$2.25

Search Stocks

Summary

Name Age Since Current Position

James Stauner

56 2011 Independent Chairman of the Board

Robert Kill

2013 President, Chief Executive Officer, Director

Brett Reynolds

44 2013 Chief Financial Officer, Senior Vice President

Suranjan Roychowdhury

2014 Vice President - Research & Development and Clinical Affairs

David Perry

2013 Vice President - Marketing

Marc Herregraven

47 2002 Vice President - Manufacturing

Daniel Merz

2014 Vice President - Healthcare Affairs

Arie Koole

48 2000 Corporate Controller, Managing Director - Dutch Operations

Kenneth Paulus

55 2014 Director

R. Patrick Maxwell

68 2011 Independent Director

Kevin Roche

62 2014 Independent Director

Sven Wehrwein

63 2006 Independent Director

Doug Sherk

IR Contact Officer

Biographies

Name Description

James Stauner

Mr. James P. Stauner is Independent Chairman of the Board of Uroplasty Inc. since November 2011. Mr. Stauner has over 30 years of experience in the healthcare industry. Since July 2005, he has been an Operating Partner with Roundtable Healthcare Partners, a private equity firm focused on the healthcare industry. Prior to joining Roundtable Healthcare Partners, Mr. Stauner held various positions between 1999 and 2005 at Cardinal Health, Inc., most recently as President of the Manufacturing Business Groups and a member of the Senior Management Operating Committee. Mr. Stauner has knowledge of the healthcare industry and of the characteristics sought by a private equity firm for investment in the healthcare industry, and experience in operating and managing a medical products business and in finance.

Robert Kill

Mr. Robert E. Kill is President, Chief Executive Officer, Director of Uroplasty Inc. Mr. Kill is currently an Operating Partner with Altamont Capital Partners, a private equity firm. Prior to joining Altamont, Mr. Kill was President and Chief Executive Officer of Virtual Radiologic Corporation, a provider of technology-enabled outsourced radiology solutions. Before Virtual Radiologic, he was President of Misys Physician Systems, a developer of electronic medical record and practice management software. Mr. Kill was with Baxter Healthcare for the first ten years of his career, where he held senior leadership roles in operations, marketing and sales.

Brett Reynolds

Mr. Brett A. Reynolds has been appointed as Chief Financial Officer, Senior Vice President of Uroplasty, Inc., with effect from August 12, 2013. Mr. Reynolds experience spans more than 20 years in finance and operations. He was most recently the CFO of Synovis, staying on with the company as Site Leader following its sale to Baxter International in February 2012 for $325 million. Prior to Synovis, Mr. Reynolds served in executive financial positions at Chiquita Processed Foods, Arthur Andersen and Deloitte & Touche. Mr. Reynolds is a Certified Public Accountant and holds a BA in Accounting and an MBA from the University of Minnesota'sCarlson School of Management. He was the Chief Financial Officer, Vice President of Finance and Corporate Secretary of Synovis Life Technologies, Inc., a publicly-held medical device manufacturer headquartered in the Twin Cities. From 2012 until becoming an officer of Uroplasty, Mr. Reynolds was the site leader of Baxter in the Twin Cities responsible for the remainder of the Synovis operations.

Suranjan Roychowdhury

Dr. Suranjan Roychowdhury is the Vice President - Research & Development and Clinical Affairs of Uroplasty, Inc. Dr. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices. Dr. Roychowdhury served for more than eight years in advancing executive roles with American Medical Systems, including leadership of R&D as well as the Clinical, Regulatory, and Healthcare Economics functions for the $230 million Men's Health division. Most recently, Dr. Roychowdhury was with Vascular Solutions, a Minnesota-based cardiovascular medical device company. He has also served in executive roles with Sulzer Spine-Tech (now Zimmer Spine), Boston Scientific, and Schneider USA (Pfizer). Dr. Roychowdhury holds a B.Tech in Metallurgical Engineering from the Indian Institute of Technology at Varanasi, and M.S. and Ph.D. degrees in Materials Science & Engineering from the University of Delaware. He is the author of several publications on urology and cardiovascular topics. In addition, he holds 20 issued US patents for medical devices in Cardiology, Orthopedics, Urology and Drug Delivery.

David Perry

Mr. David B. Perry is Vice President - Marketing of the company. He joins Uroplasty with nearly 20 years of experience developing, branding and commercializing medical device products resulting in market leadership, share gains and new sales opportunities in global markets. Mr. Perry's experience includes more than 10 years directing domestic and global product marketing initiatives in the endourology, prostate and men's health divisions at American Medical Systems (AMS), an Endo Health Solutions company. Prior to joining AMS, Mr. Perry held key marketing roles at Boston Scientific and Kendall Healthcare (Covidien, Inc.). Mr. Perry holds a Bachelor of Science degree from Brigham Young University'sMarriott School of Management.

Marc Herregraven

Mr. Marc M. Herregraven is Vice President - Manufacturing of Uroplasty Inc. since November 2002. He joined Bioplasty, Inc. in April 1992 as Plant Manager, and became Director of Manufacturing in 1994 and Director of Operations in 1999. Previously, he served with Advanced Bio-Surfaces, Inc., a Minnesota-based medical device developer, as Director of Manufacturing, and with Bio-Vascular, Inc., a Minnesota-based medical device manufacturer, in an engineering function.

Daniel Merz

Mr. Daniel P. Merz is Vice President - Healthcare Affairs of the Company. He joins Uroplasty with fifteen years of medical device experience, specifically in driving commercial success through enhanced reimbursement, novel clinical research and efficient regulatory clearances. Mr. Merz has a deep background in strategic planning, process reengineering and successful influence on medical organizations and reimbursement policy. Most recently, he directed the clinical affairs program at St. Jude Medical in Plymouth, Minnesota, where he was accountable for the global trans-catheter and surgical heart valve clinical programs. Prior to that, he oversaw the clinical and regulatory team supporting the global BPH capital equipment business in Minnesota and California for American Medical Systems, a leading medical device manufacturer specializing in urology and pelvic health. Mr. Merz holds a Bachelor of Science degree from Northwestern University in Biomedical Engineering.

Arie Koole

Mr. Arie J. Koole is the Corporate Controller, Managing Director - Dutch Operations Uroplasty Inc. He joined the company in 1993 and has served as Corporate Controller and Managing Director of the company's operations in The Netherlands since January 2000. From 1987 to 1993, Mr. Koole was a financial auditor with the international accounting firm Deloitte & Touche in The Netherlands.

Kenneth Paulus

Kenneth H. Paulus has been appointed as Director of Uroplasty, Inc., effective October 15, 2014. Before joining Allina Health in 2005, Mr. Paulus was President and Chief Executive Officer of Massachusetts-based HealthOne Care System, one of the nation's largest integrated physician organizations and a teaching and research affiliate of Harvard Medical School. Before his time at HealthOne, he served as the Chief Operating Officer of Boston-based Partners Community HealthCare/Partners HealthCare System. Partners HealthCare System is a teaching affiliate of Harvard Medical School that includes two of the nation's leading hospitals - Massachusetts General Hospital and Brigham and Women's Hospital. Mr. Paulus currently serves on the Board of Overseers for the University of Minnesota Carlson School of Business, is a trustee with Hamline University, and serves on the executive committee and board of directors for the Minnesota Hospital Association. He is a graduate of the University of Minnesota Masters Program in Healthcare Administration.

R. Patrick Maxwell

Mr. R. Patrick Maxwell is Independent Director of Uroplasty Inc since June 2006. He has served as Chairman of the Board from June 2006 through November 2011. Mr. Maxwell has over 30 years of experience as a turnaround management specialist, an entrepreneur and executive in both the business and non-profit sectors. He has served as Chief Financial Officer of Tele Resources, Inc. since October 1996. He previously served as Chief Executive Officer of Entronix Inc., Northern Supply, Inc., and Telnet Systems, Inc. He also previously served as Chief Financial Officer of Magnum Tire Corporation, Midwest Legal Services, Inc. and Templeton and Associates, Inc.

Kevin Roche

Mr. Kevin H. Roche is Independent Director of the Company. Mr. Roche’s background includes more than 30 years in legal, advisory, and executive operating roles within the healthcare industry. He previously served as the General Counsel of UnitedHealth Group, later becoming CEO of their Ingenix division. He currently leads Roche Consulting, LLC, a general health care consulting and investing firm providing strategic, operational, legal and other business advice to industry clients. Mr. Roche also served as managing partner at Vita Advisors LLC, a healthcare mergers and acquisition advisory firm. Mr. Roche earned his J.D. from the University of Minnesota Law School, received his M.B.A. from the University of Minnesota’s Carlson School of Business, and has a B.S. degree from Pace University. Mr Roche currently serves on the Board of Directors of Medication Management Systems, Tactile Systems, Oak Street Health and MedPricer. Previously, he served on the Board of several other leading healthcare companies including vRad (Virtual Radiologic) and Genoa Healthcare.

Sven Wehrwein

Mr. Sven A. Wehrwein is Independent Director of Uroplasty Inc since August 2006. He has over 35 years of experience in accounting, corporate finance and investment banking. Mr. Wehrwein also serves on the board of directors of Proto Labs, Inc., a manufacturer of Internet-enabled custom molded parts, and SPS Commerce, Inc., a supply-chain management software company, both of which are reporting companies. Mr. Wehrwein also served on the board of Compellent Technologies, Inc. from 2007 until its acquisition by Dell Inc. in 2011, on the board of Vital Images, Inc. from 1997 until its acquisition by Toshiba Medical Systems Corp. in 2011, on the board of Synovis Life Technologies, Inc. from 2004 until its acquisition by Baxter International Inc. in 2012, and on the board of Image Sensing Systems, Inc. from 2006 until 2012.

Doug Sherk

Search Stocks